Details and Advantages
Applications:
ELISA,Flow Cyt
Reactivity:
Human SLAMF7/CD319
Conjugate:
Unconjugated
Advantages:
High lot-to-lot consistency
Increased sensitivity and higher affinity
Animal-free production
Summary
>
Description:
Anti-SLAMF7/CD319(Azintuxizumab Biosimilar) Antibody is a biosimilar antibody directed against Human SLAMF7/CD319.
Isotype: Human IgG1
Conjugate: Unconjugated
Specificity: Human SLAMF7/CD319
Clonality: Monoclonal
Purity: Recombinant Expression and Affinity purified
Concentration: 1mg/ml
Formation: Liquid, 10mM PBS (pH 7.5)
Storage: Store at –20 °C, (Avoid freeze/thaw cycles)
Anti-SLAMF7/CD319(Azintuxizumab Biosimilar) Antibody is a biosimilar antibody directed against Human SLAMF7/CD319.
Isotype: Human IgG1
Conjugate: Unconjugated
Specificity: Human SLAMF7/CD319
Clonality: Monoclonal
Purity: Recombinant Expression and Affinity purified
Concentration: 1mg/ml
Formation: Liquid, 10mM PBS (pH 7.5)
Storage: Store at –20 °C, (Avoid freeze/thaw cycles)
Performance
>
ELISA: 1:5000-1:20000
Flow Cyt: 1:200-1:1000
Other tested applications.
Dilution factors are presented in the form of a range because the optimal dilution is a function of many factors, such as antigen density, permeability, etc. The actual dilution used must be determined empirically.
